India gets a third Vaccine approved by the DGCI

Just In –

India on Monday granted Emergency Authorization Usage (EUA) of Russia’s Sputnik V corona vaccine just after the day it registered the biggest spike in the cases since the beginning of the pandemic. Close to 1.7L cases and 904 deaths registered in a single day in India with Maharashtra topping the tally with 63k cases accounting for close to 37% of the total cases, followed by Uttar Pradesh (UP) with 15k and Delhi with 10k cases respectively. India overtook Brazil as the second most-affected country with overall tally of 13.53million cases till today.

“India currently has 2 COVID-19 vaccines being manufactured locally: Covishield and Covaxin, and we can expect five more vaccines by Q3 2021. These vaccines are Sputnik V vaccine (in collaboration with Dr. Reddy’s), Johnson & Johnson vaccine (in collaboration with Biological E), Novavax vaccine (in collaboration with Serum India), Zydus Cadila’s vaccine, and Bharat Biotech’s Intranasal Vaccine. Safety and efficacy are the Union government’s primary concerns while granting emergency use authorisation (EUA) to any COVID-19 vaccine in the country. “- source ANI

Russia registered Sputnik V for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September. And now Indian authorities have granted the access for its emergency usage. Earlier in September Dr. Reddy had partnered with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V and for its distribution rights in India. The DCGI (Drugs Controller General of India) is yet to decide on the SEC recommendation.
Also, with the news of Sputnik V getting approved, spreading like a wildfire; Dr. Reddy’s shares price skyrocketed about 4% in just an hour’s time and surged 7.57% by the day’s end.

About Dhruv

Leave a Reply

Your email address will not be published.


Lorem Ipsum is simply dummy text of the printing

Add Contact Form 7 shortcode here